3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Active not recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
78
Melanoma
51
Squamous Cell Carcinoma of Head and Neck
40
Neoplasm Metastasis
30
Neoplasms
27
Breast Neoplasms
26
Colorectal Neoplasms
23
Carcinoma, Renal Cell
23
Head and Neck Neoplasms
21
Triple Negative Breast Neoplasms
20
Carcinoma, Transitional Cell
20
Stomach Neoplasms
19
Ovarian Neoplasms
17
Lung Neoplasms
15
Uterine Cervical Neoplasms
12
Esophageal Neoplasms
12
Carcinoma, Hepatocellular
12
Urinary Bladder Neoplasms
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
11
Pancreatic Neoplasms
10
Small Cell Lung Carcinoma
9
Multiple Myeloma
9
Recurrence
8
Endometrial Neoplasms
8
Carcinoma, Merkel Cell
8
Lymphoma, Non-Hodgkin
7
Lymphoma
7
Skin Neoplasms
6
Mesothelioma
6
Hodgkin Disease
6
Interventions
Gemcitabine
2
rucaparib
1
romidepsin
1
pembrolizumab
1
enfortumab vedotin
1
Trastuzumab
1
Standard of Care
1
Sorafenib
1
Paclitaxel
1
Depsipeptides
1
Crizotinib
1
Cisplatin
1
Carboplatin
1
Afatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Urethral Neoplasms
×
pembrolizumab
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA